Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694581 | 0.86 | SLC2A1 (0.53) | SLC2A1KCNH2KDM4ETSHR | |
| SCHEMBL3685796 | 0.86 | SLC2A1 (0.53) | SLC2A1KCNH2KDM4ETSHR | |
| SCHEMBL5652953 | 0.86 | SLC2A1 (0.53) | SLC2A1KCNH2KDM4ETSHR | |
| SCHEMBL5438226 | 0.83 | IRAK1 (0.42) | SLC2A1MTNR1AMTNR1B | |
| SCHEMBL3779200 | 0.82 | SLC2A1 (0.47) | SLC2A1KCNH2MTNR1AMTNR1BLMNA | |
| SCHEMBL3776044 | 0.81 | SLC2A1 (0.41) | SLC2A1KCNH2MTNR1AMTNR1BKDM4E | |
| SCHEMBL5435565 | 0.81 | KCNH2 (0.40) | SLC2A1KCNH2KDM4EKDM2B | |
| SCHEMBL5426592 | 0.81 | KCNH2 (0.42) | SLC2A1KCNH2MTNR1AMTNR1BMAPT | |
| SCHEMBL1527047 | 0.80 | KCNH2 (0.57) | SLC2A1KCNH2KDM4ELMNA | |
| SCHEMBL1526894 | 0.80 | KCNH2 (0.57) | SLC2A1KCNH2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| CN-101035785-A | Novel compounds having an anti-bacterial activity | MORPHOCHEM AG KOMB CHEMIE (DE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | SLC2A1 4714/4885KCNH2 3363/4885MTNR1A 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.